Published in Antiviral Res on December 01, 2010
Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio (2011) 1.21
Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res (2010) 1.15
Clinical evaluation of microbicide formulations. Antiviral Res (2010) 1.05
Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J Virol (2011) 0.97
Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains. AIDS Res Hum Retroviruses (2012) 0.93
Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus. Antimicrob Agents Chemother (2011) 0.84
Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy. PLoS One (2013) 0.84
Advances in HIV microbicide development. Future Med Chem (2011) 0.81
Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study. PLoS One (2015) 0.79
Improving preclinical models of HIV microbicide efficacy. Trends Microbiol (2015) 0.78
Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1. Mol Biol Int (2012) 0.77
Comparison of the effect of semen from HIV-infected and uninfected men on CD4+ T-cell infection. AIDS (2016) 0.75
Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimicrob Agents Chemother (2013) 0.75
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health (2013) 1.05
Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci (2012) 1.03
Multipurpose prevention technologies: products in development. Antiviral Res (2013) 1.00
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release (2012) 0.87
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother (2012) 0.81
Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient. J Pharm Sci (2013) 0.78
Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies. Antiviral Res (2013) 0.77
Development of a UC781 releasing polyethylene vinyl acetate vaginal ring. Drug Deliv Transl Res (2012) 0.76
Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring. Eur J Pharm Biopharm (2013) 0.75
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings. J Biomed Mater Res B Appl Biomater (2012) 0.75